T. Rowe Price Investment Management, Inc. Repligen Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Repligen Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 260,848 shares of RGEN stock, worth $32.9 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
260,848
Previous 159,057
64.0%
Holding current value
$32.9 Million
Previous $22.9 Million
44.97%
% of portfolio
0.02%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding RGEN
# of Institutions
495Shares Held
57.6MCall Options Held
75.6KPut Options Held
521K-
Black Rock Inc. New York, NY7.57MShares$954 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.57MShares$954 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$641 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$213 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.67MShares$211 Million0.04% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....